Moberg Derma Has Completed Recruitment for MOB-015 Phase II Clinical Study
STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Derma AB (OMX: MOB) has successfully completed the recruitment of 237 patients with nail fungus (onychomycosis) to participate in the ongoing MOB-015 phase II study. MOB-015 is the company’s second-generation topical treatment for nail fungus.